Do antibodies stimulate myelin repair in multiple sclerosis?

Dorian Mcgavern, Kunihiko Asakura, Moses Rodriquez

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeutic intervention that mimics the intrinsic reparative process and results in longterm clinical improvement. As yet, the therapeutic strategies tested in MS have failed to accomplish this task. However, one potential therapy that has shown some promise in rodent models of demyelination involves the administration of antibodies. Studies in various models of demyelination (virus-induced, autoimmune, and toxic) indicate that a subset of autoantibodies with reactivity to CNS antigens promote remyelination. We have identified a prototypic germline IgMk monoclonal antibody, designated SCH 94.03, with reactivity to a surface antigen on oligodendrocytes that promotes CNS remyelination. This antibody has the phenotypic features of polyreactive physiological natural autoantibodies. Additionally, treatment of MS patients with intravenous immunoglobulin, which contains these natural autoantibodies, may be efficacious in a subset of patients. We propose three mechanisms (direct stimulation of oligodendrocytes, immunomodulation, and opsonization of debris) by which polyreactive natural autoantibodies directed against CNS antigen may promote remyelination. Remyelination has the potential to not only improve conduction velocity but also may protect axons from injury and improve neurological function.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalNeuroscientist
Volume5
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Myelin Sheath
Autoantibodies
Multiple Sclerosis
Antibodies
Oligodendroglia
Demyelinating Diseases
Antigens
Immunomodulation
Poisons
Intravenous Immunoglobulins
Therapeutics
Surface Antigens
Axons
Rodentia
Monoclonal Antibodies
Viruses
Wounds and Injuries

Keywords

  • Autoantibodies
  • Oligodendrocytes
  • Remyelination
  • Theiler's virus

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Do antibodies stimulate myelin repair in multiple sclerosis? / Mcgavern, Dorian; Asakura, Kunihiko; Rodriquez, Moses.

In: Neuroscientist, Vol. 5, No. 1, 1999, p. 19-28.

Research output: Contribution to journalArticle

Mcgavern, Dorian ; Asakura, Kunihiko ; Rodriquez, Moses. / Do antibodies stimulate myelin repair in multiple sclerosis?. In: Neuroscientist. 1999 ; Vol. 5, No. 1. pp. 19-28.
@article{cc5297d2000448188dfc4d7b1fc5e0de,
title = "Do antibodies stimulate myelin repair in multiple sclerosis?",
abstract = "One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeutic intervention that mimics the intrinsic reparative process and results in longterm clinical improvement. As yet, the therapeutic strategies tested in MS have failed to accomplish this task. However, one potential therapy that has shown some promise in rodent models of demyelination involves the administration of antibodies. Studies in various models of demyelination (virus-induced, autoimmune, and toxic) indicate that a subset of autoantibodies with reactivity to CNS antigens promote remyelination. We have identified a prototypic germline IgMk monoclonal antibody, designated SCH 94.03, with reactivity to a surface antigen on oligodendrocytes that promotes CNS remyelination. This antibody has the phenotypic features of polyreactive physiological natural autoantibodies. Additionally, treatment of MS patients with intravenous immunoglobulin, which contains these natural autoantibodies, may be efficacious in a subset of patients. We propose three mechanisms (direct stimulation of oligodendrocytes, immunomodulation, and opsonization of debris) by which polyreactive natural autoantibodies directed against CNS antigen may promote remyelination. Remyelination has the potential to not only improve conduction velocity but also may protect axons from injury and improve neurological function.",
keywords = "Autoantibodies, Oligodendrocytes, Remyelination, Theiler's virus",
author = "Dorian Mcgavern and Kunihiko Asakura and Moses Rodriquez",
year = "1999",
doi = "10.1177/107385849900500104",
language = "English (US)",
volume = "5",
pages = "19--28",
journal = "Neuroscientist",
issn = "1073-8584",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Do antibodies stimulate myelin repair in multiple sclerosis?

AU - Mcgavern, Dorian

AU - Asakura, Kunihiko

AU - Rodriquez, Moses

PY - 1999

Y1 - 1999

N2 - One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeutic intervention that mimics the intrinsic reparative process and results in longterm clinical improvement. As yet, the therapeutic strategies tested in MS have failed to accomplish this task. However, one potential therapy that has shown some promise in rodent models of demyelination involves the administration of antibodies. Studies in various models of demyelination (virus-induced, autoimmune, and toxic) indicate that a subset of autoantibodies with reactivity to CNS antigens promote remyelination. We have identified a prototypic germline IgMk monoclonal antibody, designated SCH 94.03, with reactivity to a surface antigen on oligodendrocytes that promotes CNS remyelination. This antibody has the phenotypic features of polyreactive physiological natural autoantibodies. Additionally, treatment of MS patients with intravenous immunoglobulin, which contains these natural autoantibodies, may be efficacious in a subset of patients. We propose three mechanisms (direct stimulation of oligodendrocytes, immunomodulation, and opsonization of debris) by which polyreactive natural autoantibodies directed against CNS antigen may promote remyelination. Remyelination has the potential to not only improve conduction velocity but also may protect axons from injury and improve neurological function.

AB - One of the major goals in the study of multiple sclerosis (MS) is to identify a beneficial therapeutic intervention that mimics the intrinsic reparative process and results in longterm clinical improvement. As yet, the therapeutic strategies tested in MS have failed to accomplish this task. However, one potential therapy that has shown some promise in rodent models of demyelination involves the administration of antibodies. Studies in various models of demyelination (virus-induced, autoimmune, and toxic) indicate that a subset of autoantibodies with reactivity to CNS antigens promote remyelination. We have identified a prototypic germline IgMk monoclonal antibody, designated SCH 94.03, with reactivity to a surface antigen on oligodendrocytes that promotes CNS remyelination. This antibody has the phenotypic features of polyreactive physiological natural autoantibodies. Additionally, treatment of MS patients with intravenous immunoglobulin, which contains these natural autoantibodies, may be efficacious in a subset of patients. We propose three mechanisms (direct stimulation of oligodendrocytes, immunomodulation, and opsonization of debris) by which polyreactive natural autoantibodies directed against CNS antigen may promote remyelination. Remyelination has the potential to not only improve conduction velocity but also may protect axons from injury and improve neurological function.

KW - Autoantibodies

KW - Oligodendrocytes

KW - Remyelination

KW - Theiler's virus

UR - http://www.scopus.com/inward/record.url?scp=0032961597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032961597&partnerID=8YFLogxK

U2 - 10.1177/107385849900500104

DO - 10.1177/107385849900500104

M3 - Article

VL - 5

SP - 19

EP - 28

JO - Neuroscientist

JF - Neuroscientist

SN - 1073-8584

IS - 1

ER -